These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

951 related items for PubMed ID: 28684402

  • 21. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.
    J Clin Oncol; 2013 May 10; 31(14):1767-74. PubMed ID: 23569304
    [Abstract] [Full Text] [Related]

  • 22. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
    Kozar I, Cesi G, Margue C, Philippidou D, Kreis S.
    Biochim Biophys Acta Gen Subj; 2017 Nov 10; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
    [Abstract] [Full Text] [Related]

  • 23. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ.
    Neoplasia; 2010 Aug 10; 12(8):637-49. PubMed ID: 20689758
    [Abstract] [Full Text] [Related]

  • 24. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A, Cohen MS.
    Expert Opin Drug Discov; 2016 Sep 10; 11(9):907-16. PubMed ID: 27327499
    [Abstract] [Full Text] [Related]

  • 25. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T, Makino E, Krueger MA, Velic A, Macek B, Rothbauer U, Groll N, Pötz O, Czemmel S, Niessner H, Meier F, Ikenberg K, Garbe C, Schittek B.
    EBioMedicine; 2016 Jun 10; 8():132-149. PubMed ID: 27428425
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
    Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S.
    Nature; 2014 Sep 04; 513(7516):105-9. PubMed ID: 25079330
    [Abstract] [Full Text] [Related]

  • 29. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct 04; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, Ribas A, Di Napoli A, Torrisi MR, Aurisicchio L, Ascierto PA, Mancini R, Ciliberto G.
    Oncotarget; 2015 Sep 22; 6(28):24823-41. PubMed ID: 26208478
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib.
    Mondru AK, Wilkinson B, Aljasir MA, Alrumayh A, Greaves G, Emmett M, Albohairi S, Pritchard-Jones R, Cross MJ.
    FEBS Lett; 2024 Aug 22; 598(16):2011-2027. PubMed ID: 38977937
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status.
    Komina AV, Palkina NV, Aksenenko MB, Lavrentev SN, Moshev AV, Savchenko AA, Averchuk AS, Rybnikov YA, Ruksha TG.
    Melanoma Res; 2019 Oct 22; 29(5):544-548. PubMed ID: 31116162
    [Abstract] [Full Text] [Related]

  • 37. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.
    Lancet Oncol; 2014 Apr 22; 15(4):436-44. PubMed ID: 24582505
    [Abstract] [Full Text] [Related]

  • 38. Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway.
    Gad SA, Ali HEA, Gaballa R, Abdelsalam RM, Zerfaoui M, Ali HI, Salama SH, Kenawy SA, Kandil E, Abd Elmageed ZY.
    Sci Rep; 2019 Oct 02; 9(1):14197. PubMed ID: 31578454
    [Abstract] [Full Text] [Related]

  • 39. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R.
    Cancer Discov; 2013 Feb 02; 3(2):158-67. PubMed ID: 23242808
    [Abstract] [Full Text] [Related]

  • 40. miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.
    Nguyen MT, Lin CH, Liu SM, Miyashita A, Ihn H, Lin H, Ng CH, Tsai JC, Chen MH, Tsai MS, Lin IY, Liu SC, Li LY, Fukushima S, Lu J, Ma N.
    Neoplasia; 2020 Dec 02; 22(12):789-799. PubMed ID: 33142243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.